Abstract：
Circulating tumor cells (CTCs) detection presents significant advantages in diagnosing liver cancer due to its noninvasiveness, real-time monitoring, and dynamic tracking. However, the clinical application of CTCs-based diagnosis is largely limited by the challenges of capturing low-abundance CTCs within a complex blood environment while ensuring them alive. Here, an ultrastrong ligand, l-histidine-l-histidine (HH), specifically targeting sialylated glycans on the surface of CTCs, is designed. Furthermore, HH is integrated into a cell-imprinted polymer, constructing a hydrogel with precise CTCs imprinting, high elasticity, satisfactory blood compatibility, and robust anti-interference capacities. These features endow the hydrogel with excellent capture efficiency (>95%) for CTCs in peripheral blood, as well as the ability to release CTCs controllably and alive. Clinical tests substantiate the accurate differentiation between liver cancer, cirrhosis, and healthy groups using this method. The remarkable diagnostic accuracy (94%), lossless release of CTCs, material reversibility, and cost-effectiveness ($6.68 per sample) make the HH-based hydrogel a potentially revolutionary technology for liver cancer diagnosis and single-cell analysis.
摘要：
循环肿瘤细胞（CTCs）检测显示在诊断肝癌的显著优势，由于其非侵袭性，实时监控,动态跟踪。然而,基于CTC的诊断的临床应用在很大程度上受到在复杂的血液环境中捕获低丰度CTC同时确保其存活的挑战的限制.在这里我们设计了一个超强配体,L-组氨酸-L-组氨酸(HH),特异性靶向CTC表面上的唾液酸化聚糖。进一步将HH整合到细胞印迹聚合物中，构建具有精确CTC印迹的水凝胶，高弹性,令人满意的血液相容性，和强大的抗干扰能力。这些特征赋予水凝胶对外周血中CTC的优异捕获效率(>95%),以及可控和有效释放CTC的能力。临床试验证实了肝癌之间的准确区分，肝硬化,和使用这种方法的健康群体。显著的诊断准确率（94%），CTC的无损释放，材料可逆性，和成本效益（每个样品6.68美元）使基于HH的水凝胶成为肝癌诊断和单细胞分析的潜在革命性技术。本文受版权保护。保留所有权利。
